Novelos Therapeutics, Inc. Announces Presentation of Encouraging Results in Phase 2 Ovarian Cancer Trial at 2008 American Society of Clinical Oncology Meeting by MGH and Novelos Therapeutics, Inc./Harvard Cancer Centers

NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Massachusetts General Hospital (MGH) Cancer Center and Dana-Farber/Harvard Cancer Center (DF/HCC) presented a poster highlighting encouraging results from a Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO) now taking place in Chicago, Illinois. Carolyn Krasner, MD, medical oncologist and a recognized expert in ovarian cancer at the Massachusetts General Hospital Cancer Center, is the Principal Investigator. The poster, NOV-002 Plus Carboplatin Yields Disease Stability in Platinum-Resistant Ovarian Cancer, can be viewed at www.novelos.com ‘Our Products’, ‘NOV-002’ section.